National Institutes of Health: Triple Negative Breast Neoplasms trials

The registry lists 34 Triple Negative Breast Neoplasms studies with National Institutes of Health as lead sponsor. 6 are open to participants now and 16 have results posted.

Phase 1 20Phase 2 12Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain MetastasesRecruitingNCT07619534
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingNCT07137416Phase 1
• A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)RecruitingNCT07067138Not applicable
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerRecruitingNCT05422794Phase 1
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerRecruitingNCT05111561Phase 1
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT03606967Phase 2
• T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial CancersTerminatedNCT05035407Phase 1Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingNCT04345913Phase 1/2Results posted
• BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedNCT04296942Phase 1Results posted
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerActive, not recruitingNCT02883062Phase 2Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01964924Phase 2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingNCT01116648Phase 1/2Results posted
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCompletedNCT00861705Phase 2Results posted
• Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerWithdrawnNCT06590558Phase 1
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTerminatedNCT02474173Phase 1
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01624441Phase 1
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedNCT01238133Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1